Purchase Order 75N93018P01035

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,810.00 on August 18, 2020. The order covers biomedical reagents and research materials to be supplied from San Diego, California with a completion date of September 16, 2020. No set-aside applied.</p>

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $22,041.90 purchase order to Biolegend, Inc., a medical division of Revvity Inc., for BIOLEGEND ANTIBODIES. The firm fixed price order runs from September 1, 2023 through October 31, 2023 for place of performance in San Diego, California. No major subcontractors or set aside designations were indicated. This small purchase supports the NIH/NIAID's research...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for COVID-19 reagents with a ceiling value of $26,145.00, effective April 9, 2021. Performance is located in San Diego, California, with an ultimate completion date of May 7, 2021. The order is firm fixed price with no small business set-aside.</p>

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, awarded a $56,762.00 firm-fixed-price purchase order to Biolegend, Inc. for the supply of various biological research products, including Alexa Fluor 700 anti-human IFN-γ and several Brilliant Violet-labeled antibodies for human cellular markers. This acquisition was processed under Simplified Acquisition Procedures without a small business set-aside. Biolegend, a...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for 83 brilliant violet antibodies valued at $20,818.35, with an award date of December 31, 2019 and ultimate completion date of December 30, 2020. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation.</p>

This purchase order, awarded to Biolegend, Inc. on September 17, 2021, represents an administrative action by the National Institute of Allergy and Infectious Diseases (NIAID) to de-obligate $10,568 in unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a). The contract, which was ultimately completed on October 17, 2021, is structured as a firm fixed-price purchase order with no small business set-aside designation. The place of performance is located in...

This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH), to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies. The $16,199.95 contract is for the delivery of BIOLEGEND antibodies to support NIAID's research initiatives, which may include studies related to COVID-19, immunology, and other disease areas. The contract does not...

This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....

<p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Becton, Dickinson and Company on August 30, 2018, with a ceiling value of $8,642.30 for fluorescently conjugated monoclonal antibodies for research and pre-clinical monitoring of vaccine applications and flow cytometry consumables.</p> <p>Place of performance is San Jose, CA. The order is firm fixed price with an ultimate completion date of September 11, 2018. No set-aside was used.</p>